Scientific Program (All times are CET)

Session 1: Smoldering myeloma: what’s next?
How to define high risk smoldering myeloma
Irene Ghobrial, USA
How to treat high risk smoldering myeloma
Maria Victoria Mateos, Spain
Round table discussion
Irene Ghobrial, USA,  Maria Victoria Mateos, Spain, S. Vincent Rajkumar, USA, Mario Boccadoro, Italy
Session 2: Therapy of transplant eligible patients
Novel induction regimens
Philippe Moreau, France
Maintenance therapy
Graham Jackson, UK
Round table discussion
Philippe Moreau, France, Graham Jackson, UK, Paul Richardson, USA, Francesca Gay, Italy
Session 3: Plenary lecture
Role and perspectives of MRD in myeloma
Jesus San Miguel, Spain
Round table discussion
Jesus San Miguel, Spain, Herve Avet-Loiseau, France,  Bruno Paiva, Spain, Kwee Yong, UK
Industry-sponsored symposium (GSK)
To complete the post-symposium survey – click here
Session 4: Therapy of transplant ineligible patients
Frailty assessment
Sonja Zweegman, The Netherland
Novel regimens in elderly patients
Thierry Facon, France
Round table discussion
Sonja Zweegman, The Netherland, Thierry Facon, France, Alessandra Larocca, Italy,  Maria Victoria Mateos, Spain
Session 5: Selected oral communications
UPDATED PHASE 1B RESULTS FROM CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-4528 CAR-T CELL THERAPY IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM)
Presenter: Andrzej Jakubowiak, USADREAMM-2: BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITHMULTIPLE MYELOMA REFRACTORY TO PROTEASOME INHIBITORS, IMMUNOMODULATORY AGENTS, AND REFRACTORY/INTOLERANT TO ANTI-CD38 MAB, INCLUDING SUBGROUPS WITH RENAL IMPAIRMENT (RI) AND HIGH-RISK (HR) CYTOGENETICS
Presenter: Lonial Sagar, USADREAMM-5: PLATFORM TRIAL EVALUATING BELANTAMAB MAFODOTIN (A BCMA-DIRECTED IMMUNO-CONJUGATE) IN COMBINATION WITH NOVEL AGENTS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Presenter: Ira Gupta, USAFINAL ANALYSIS OF A PHASE I-b STUDY OF ISATUXIMAB COMBINED WITH CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): (NCT-02332850)
Presenter: Tom Martin, USA

OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE REMAIN COMPARABLE TO THE OUTCOMES REPORTED IN THE PHASE 3 TOURMALINE-MM1 STUDY
Presenter: Xavier Leleu, France

HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO POMALIDOMIDE AND/OR AN ANTI-CD38 MONOCLONAL ANTIBODY (MAB) – FINAL PRIMARY ANALYSIS
Presenter: Paul Richardson, USA

ORAL IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (IRD) VERSUS PLACEBO-RD FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS INELIGIBLE FOR TRANSPLANT: THE MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TOURMALINE MM2 TRIAL
Presenter: Thierry Facon, France

Industry-sponsored symposium (Sanofi)
Session 6: Therapy of relapsed/refractory myeloma
Anti-CD38-based combinations
Saad Usmani, USA
IMiDs: past, present and future
Xavier Leleu, France
Round table discussion
Saad Usmani, USA, Xavier Leleu, France, Enrique M.  Ocio, Spain,  Cyril Touzeau, France,  Shaji Kumar, USA
Session 7: Immunotherapy for myeloma
Bispecific antibodies
Luciano Costa, USA
CAR-T Cells
Noopur Raje, USA
Round table discussion
Luciano Costa, USA, Noopur Raje, USA, Salomon Manier, France, Sagar Lonial, USA
Session 8: Plenary lecture
Multiple Myeloma Excellence Award ceremony
Presented to: Saad Usmani, USA by Congress Co-Chairs
Multiple Myeloma Excellence Award lecture
Saad Usmani, USA
Management of Al amyloidosis: what’s new?
Giampaolo Merlini, Italy
Industry-sponsored symposium (Adaptive Biotechnologies)